Risk of Dyslipidemia Associated with VEGF/VEGFR Inhibitors: A Meta-Analysis.

CONCLUSION: The use of VEGF/VEGFR inhibitors, especially the multitargeted VEGFR tyrosine kinase inhibitors (VEGFR-TKIs), was associated with higher risk of hyperlipidemia than the use of placebo, but this risk was less than that associated with mTOR or FGFR inhibitors. It indicated that clinicians need to pay close attention to the occurrence of hyperlipidemia in VEGFR-TKIs therapies. PMID: 32375082 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32375082?dopt=Abstract

Source: Translational Oncology - May 2, 2020 Category: Cancer & Oncology Authors: Dai H, Liu C, Li P, Mai Z, Tan X, Chen S, Zhou Z, Tang Z, Miao J, Liu L, Fang Y Tags: Transl Oncol Source Type: research